Table 1 Clinicopathological characteristics at baseline and treatment strategies
BM cohort (N = 12) N(%) | LM cohort (N = 16) N(%) | |
|---|---|---|
Age | ||
Median (IQR) | 60 (52–72) | 58 (53–62) |
Gender | ||
Female | 5 (41.7) | 10 (62.5) |
Male | 7 (58.3) | 6 (37.5) |
ECOG-PS | ||
0–1 | 7 (58.3) | 2 (12.5) |
2–3 | 5 (41.7) | 14 (87.5) |
Clinical stage at diagnosis | ||
IV | 7 (58.3) | 9 (56.3) |
I-III | 5 (41.7) | 7 (43.8) |
EGFR status at baseline | ||
Exon 19del | 5 (41.7) | 7 (43.8) |
Exon21 L858R | 7 (58.3) | 6 (37.5) |
Other EGFR mutations | 0 (0.0) | 3 (18.8) |
EGFR status in CSF | ||
EGFR mutations available | – | 4 (25.0) |
Negative | – | 1 (6.3) |
Unknown | – | 11 (68.8) |
CNS-related symptoms | ||
Presence | 3 (25.0) | 15 (93.8) |
Absence | 9 (75.0) | 1 (6.3) |
EGFR status prior to furmonertinib | ||
Unknown/negative | 7 (58.3) | 10 (62.5) |
T790M mutations | 3 (25.0) | 1 (6.3) |
EGFR sensitive mutations | 2 (16.7) | 5 (31.3) |
Previous lines of systemic therapy | ||
0–1 | 4 (33.3) | 11 (68.8) |
2–3 | 8 (66.7) | 5 (31.3) |
Rechallenge of 3rd generation TKI | ||
Yes | 9 (75.0) | 10 (62.5) |
No | 3 (25.0) | 6 (37.5) |
Treatment between 3rd generation TKI and furmonertinib | ||
Other TKI | 1 (11.1) | 2 (20.0) |
Chemotherapy | 5 (55.6) | 3 (30.0) |
No treatment | 3 (33.3) | 5 (50.0) |
Pre-treated/concurrent with RT | ||
Yes | 10 (83.3) | 6 (37.5) |
No | 2 (16.7) | 10 (62.5) |
Treatment strategies | ||
Furmonertinib monotherapy | 6 (50.0) | 11 (68.8) |
Furmonertinib+anti-angiogenic agent | 6 (50.0) | 5 (31.3) |
Intrathecal injection | ||
Yes | – | 9 (56.3) |
No | – | 7 (43.8) |
Regimens for intrathecal injection | ||
Pemetrexed | – | 5 (55.6) |
MTX | – | 4 (44.4) |